Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy
Xiangyu Yin, Yunjie Song, Wanglong Deng, Neil Blake, Xinghong Luo, Jia Meng · 2024
Read Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy by Xiangyu Yin, Yunjie Song, Wanglong Deng, Neil Blake, Xinghong Luo, Jia Meng (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11625675.txt.
Description
Xiangyu Yin and five co-authors review markers that predict who will benefit from cancer immunotherapy in a 2024 article. Checkpoint inhibitor drugs transformed cancer care, but they work brilliantly for some patients and fail others. Three approved markers exist: a tumor protein's level, the tumor's mutation count, and a DNA repair defect signature.
The review weighs each marker's clinical use and limits, then tours newer candidates: immune neighborhood signatures in the tumor, inherited immune gene diversity, and tumor DNA floating in blood. Combining markers into multivariable models looks promising for sharper prediction. Persistent problems include tumor variety and shifting immune surroundings. The authors say better markers are the key to truly personal immunotherapy.
Catalog record
| CREATOR | Xiangyu Yin, Yunjie Song, Wanglong Deng, Neil Blake, Xinghong Luo, Jia Meng |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |